The evolution of S100B inhibitors for the treatment of malignant melanoma.
<table>
<thead>
<tr>
<th>Title</th>
<th>The evolution of S100B inhibitors for the treatment of malignant melanoma.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Publication Type</td>
<td>Journal Article</td>
</tr>
<tr>
<td>Year of Publication</td>
<td>2013</td>
</tr>
<tr>
<td>Authors</td>
<td>Hartman, KG, McKnight, LE, Liriano, MA, Weber, DJ</td>
</tr>
<tr>
<td>Journal</td>
<td>Future Med Chem</td>
</tr>
<tr>
<td>Volume</td>
<td>5</td>
</tr>
<tr>
<td>Issue</td>
<td>1</td>
</tr>
<tr>
<td>Pagination</td>
<td>97-109</td>
</tr>
<tr>
<td>Date Published</td>
<td>2013 Jan</td>
</tr>
<tr>
<td>ISSN</td>
<td>1756-8927</td>
</tr>
<tr>
<td>Keywords</td>
<td>Antineoplastic Agents, Computer-Aided Design, Crystallography, X-Ray, Drug Design, Fluorescence Polarization</td>
</tr>
<tr>
<td>Abstract</td>
<td>Malignant melanoma continues to be an extremely fatal cancer due to a lack of viable treatment options. The evolution of S100B inhibitors for the treatment of malignant melanoma.</td>
</tr>
<tr>
<td>DOI</td>
<td>10.4155/fmc.12.191</td>
</tr>
<tr>
<td>Alternate Journal</td>
<td>Future Med Chem</td>
</tr>
<tr>
<td>PubMed ID</td>
<td>23256816</td>
</tr>
<tr>
<td>PubMed Central ID</td>
<td>PMC3575173</td>
</tr>
<tr>
<td>Grant List</td>
<td>P41 RR008119 / RR / NCRR NIH HHS / United States</td>
</tr>
<tr>
<td></td>
<td>R01 CA107331 / CA / NCI NIH HHS / United States</td>
</tr>
<tr>
<td></td>
<td>R01 GM058888 / GM / NIGMS NIH HHS / United States</td>
</tr>
<tr>
<td></td>
<td>S10 RR016812 / RR / NCRR NIH HHS / United States</td>
</tr>
<tr>
<td></td>
<td>S10 RR023447 / RR / NCRR NIH HHS / United States</td>
</tr>
<tr>
<td></td>
<td>S10 RR029601 / RR / NCRR NIH HHS / United States</td>
</tr>
<tr>
<td></td>
<td>S10 RR031729 / RR / NCRR NIH HHS / United States</td>
</tr>
</tbody>
</table>